Clinical Challenge
Free Access
Pharmacologic treatment of portal hypertension: Past, present, and future
Thomas D. Boyer M.D.,
Corresponding Author
Thomas D. Boyer M.D.
Liver Research Institute, University of Arizona Health Sciences Center, Tucson, AZ.
University of Arizona Health Sciences Center, Liver Research Institute, 245136 AHSC, Tucson, AZ 85724. fax: 520-626-5975===Search for more papers by this authorThomas D. Boyer M.D.,
Corresponding Author
Thomas D. Boyer M.D.
Liver Research Institute, University of Arizona Health Sciences Center, Tucson, AZ.
University of Arizona Health Sciences Center, Liver Research Institute, 245136 AHSC, Tucson, AZ 85724. fax: 520-626-5975===Search for more papers by this author
References
- 1 Lebrec D, Nouel O, Corbic M, Benhamou J-P. Propranolol—a medical treatment for portal hypertension? Lancet 1980; 2: 180–182.MEDLINE
- 2 D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999; 19: 475–505.MEDLINE
- 3 Luketic VA, Sanyal AJ. Esophageal varices. I. Clinical presentation, medical therapy and endoscopic therapy. Gastroenterol Clin North Am 2000; 29: 337–326.MEDLINE
- 4 D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–353.MEDLINE
- 5 Benhamou J-P, Lebrec D. Drug therapy of portal hypertension due to cirrhosis. Semin Liver Dis 1982; 2: 227–232.MEDLINE
- 6 Reynolds T. Portal hypertension, In: L Schiff, ER Schiff, eds. Diseases of the Liver. 5th ed., Philadelphia: Lippincott 1982; 393–431.
- 7 Conn HO. Cirrhosis, In: L Schiff, ER Schiff, eds. Diseases of the Liver. 5th ed., Philadelphia: Lippincott 1982; 847–977.
- 8 Boyer TD. Portal hypertension and its complications, In: D Zakim, TD Boyer, eds. Hepatology: A Textbook of Liver Diseases. 1st ed., Philadelphia: Saunders 1982; 464–499.
- 9 Conn HO, Lindenmuth WW, May CJ, Ramsby GR. Prophylactic portacaval anastomosis. A tale of two studies. Medicine 1972; 51: 27–40.
- 10 Terblanche J, Bornman PC, Jonker MAT, Kirsch RE, Saunders SJ. Injection sclerotherapy of esophageal varices. Semin Liver Dis 1982; 2: 233–241.MEDLINE
- 11 Terblanche J, Northover JMA, Bornmann P, Kahn D, Silber W, Barbezat GO, Sellars S, et al. A prospective controlled trial of sclerotherapy. I. The long-term management of patients after oesophageal variceal bleeding. Surg Gynecol Obst 1979; 148: 323–333.
- 12 Clark AW, MacDougall BRD, Westaby D, Mitchell KJ, Silk DBA, Strunin L, Dawson JL, et al. Prospective controlled trial of injection sclerotherapy in patients with cirrhosis and recent variceal haemorrhage. Lancet 1980; 2: 552–554.MEDLINE
- 13 Galambos JT, Warren WD, Rudman D. Selective and total shunts in the treatment of bleeding varices: a randomized controlled trial. N Engl J Med 1976; 295: 1089–1095.MEDLINE
- 14 Groszmann R, Kravetz D, Bosch J, Glickman M, Briux J, Bredfelt J, Conn HO, et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982; 2: 757–762.MEDLINE
- 15 Lebrec D, Poynard T, Hillon P, Benhamou J-P. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. A controlled study. N Engl J Med 1981; 305: 1371–1374.MEDLINE
- 16 Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou J-P. Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528–531.MEDLINE
- 17 Burroughs AK, McCormick PA. Long-term pharmacologic therapy of portal hypertension. Surg Clin North Am 1990; 70: 319–339.MEDLINE
- 18 Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: a cost effectiveness analysis. Gastroenterology 1997; 112: 473–482.MEDLINE
- 19 Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114: 869–873.MEDLINE
- 20 Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31: 324–329.MEDLINE
- 21 Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988–993.MEDLINE
- 22 de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846–852.MEDLINE
- 23 Chalasani N, Imperiale TF, Ismail A, Sood G, Carey M, Wilcox CM, Madichetty H, et al. Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 1999; 94: 3285–3291.MEDLINE
- 24 Boyer TD. Natural history of portal hypertension. Clin Liver Dis 1997; 1: 31–44.
- 25 Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat J-L. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. 1995: 346; 865–868.
- 26 Arroyo V. New treatments for hepatorenal syndrome. Liver Transpl 2000; 6: 287–289.MEDLINE
- 27 Hadengue A. Somatostatin or octreotide in acute variceal bleeding. Digestion 1999; 60(Suppl 2): 31–41.MEDLINE
- 28 de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999; 19: 439–455.MEDLINE
- 29 Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 63–70.MEDLINE
- 30 Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal bleeding. N Engl J Med 1996; 334: 1624–1629.MEDLINE
- 31 Lo G-H, Lai K-H, Cheng J-S, Chen M-H, Huang H-C, Hsu P-I, Lin C-K. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal bleeding: a prospective, randomized trial. Hepatology 2000; 32: 461–465.MEDLINE
- 32 Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. Ann Intern Med 1995; 123: 280–287.MEDLINE
- 33 Banares R, Moitinho E, Piqueras B, Casado M, Garica-Pagan JC, de Diego A, Bosch J. Carvedilol, a new nonselective β-blocker with intrinsic alpha-adrenergic activity, has a greater portal hypotensive effect than propronol in patients with cirrhosis. Hepatology 1999; 30; 79–83.MEDLINE
- 34 Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2–5.MEDLINE
- 35 Asbert M, Gines A, Gines P, Jimenez W, Claria J, Salo J, Arroyo V, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104: 1485–1491.MEDLINE
- 36 Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19: 397–410.MEDLINE
- 37 Rockey DC, Weisinger RA. Endothelin-induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233–240.MEDLINE
- 38 Poo J-L, Jimenez W, Munoz RM, Bosch-Marce M, Bordas N, Morales-Ruiz M, Perez M, et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology 1999; 116: 161–167.MEDLINE
- 39 Cho J-J, Hocher B, Herbst H, Jia J-D, Ruehl M, Hahn EG, Riecken EO, Shuppan D. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000; 118: 1169–1178.MEDLINE
- 40 Wiest R, Groszmann R. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411–426.MEDLINE
- 41 Martin P-Y, Gines P, Schrier R. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533–541.MEDLINE
- 42 Matsumoto A, Ogura K, Hirata Y, Kakoki M, Watanabe F, Takenaka K, Shiratori Y, et al. Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 1995; 123: 110–113.MEDLINE
- 43 Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, Ottobrelli A, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998; 129: 375–378.MEDLINE
- 44 Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial cell dysfunction in portal hypertension. Gastroenterology 1998; 114: 344–351.MEDLINE
- 45 Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741–748.MEDLINE
